Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...

By Yahoo! Finance | Nov 7, 2024 at 02:11 AM EST

Teva can benefit from US-made generics push and expects positive safety label for olanzapine LAI. Strong 2025 outlook for US generics and UZEDY patients from oral medications. TAPI divestment on track, no immediate cash impact from European fine.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.